Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03135990 · ClinicalTrials.gov registry record · NA

Using Virtual Reality in Exposure-Based Treatment for Social Anxiety in Youth

A NA study, sponsored by Weill Medical College of Cornell University.

Terminated
Registry status
NA
Development phase
19
Enrollment target

NCT03135990: Clinical Trial NA study, sponsored by Weill Medical College of Cornell University.

NCT03135990 is a NA study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03135990, a NA study, was terminated before completion, sponsored by Weill Medical College of Cornell University.

TERMINATED
Registry status
NA
Development phase
19 participants
Enrollment target

Study Summary

Anxiety disorders are the most common mental health diagnosis in the US and are associated with avoidance that causes functional impairments and decreases quality of life. Social anxiety disorder is among the most prevalent anxiety disorders, with most common age of onset being in adolescence. The frontline treatment for social anxiety disorder is cognitive behavioral therapy with exposure. However, a significant number of adolescent patients do not get better after completing cognitive behavioral therapy or experience relapse. This could be explained by findings in both mice and humans suggesting that cue-based extinction learning occurs less readily in adolescents than in children and adults. Studies using mouse-models have overcome this age disparity by enhancing contextual cues when fear extinction learning takes place. Providing realistic learning contexts for exposure could be the key to enhancing treatment effects in adolescents. This is often challenging for a variety of reasons, including difficulty realistically mimicking anxiety-provoking social situations due to limited resources, clinician training, time, or motivation. Virtual reality environments could provide contextual exposures for social anxiety. This pilot study will test the feasibility of integrating virtual reality technology in exposure-based treatment in youth ages 13-23 diagnosed with social anxiety disorder with the goal of approximating equivalent efficacy with traditional cognitive behavioral therapy, and assessing feasibility of virtual reality technology with this population. We will also pilot a fear conditioning and extinction learning paradigm to explore the relationship between extinction learning and efficacy of virtual reality exposure therapy, using physiological assessment indicators to mark changes in fear response. These markers will also be used prior to the initiation of the therapy to assess the degree to which virtual reality environments invoke a true fear response, com

Primary Outcome

Anxiety Disorders Interview Schedule is used to assess change in diagnostic status and severity of social anxiety symptoms. A low score of a 3 or below would be a sub-clinical representation of the disorder, a 4 represent moderate severity and a high score of 5-8 would be a clinically severe representation of the disorder.

Interventions

  • BEHAVIORAL Cognitive Behavioral Therapy with Virtual Reality Technology

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2018-08-14
Est. Completion 2020-03-23
Phase NA

Why NCT03135990 stopped before completion

NCT03135990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Cognitive Behavioral Therapy with Virtual Reality Technology is the first listed.

NCT03135990 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03135990 about?

NCT03135990 is a clinical study titled "Using Virtual Reality in Exposure-Based Treatment for Social Anxiety in Youth". Anxiety disorders are the most common mental health diagnosis in the US and are associated with avoidance that causes functional impairments and decreases quality of life. Social anxiety disorder is among the most prevalent anxiety disorders, with most common age of onset being in adolescence. The f...

What is the current status of trial NCT03135990?

This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2018-08-14. Estimated completion is 2020-03-23.

What interventions are being tested in trial NCT03135990?

The interventions under investigation include: Cognitive Behavioral Therapy with Virtual Reality Technology (BEHAVIORAL).

Who is sponsoring clinical trial NCT03135990?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03135990's enrollment target sits among peer trials

19 1861st of 2000 higher than 138 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03135990, the US trial registry maintained by the National Library of Medicine. NCT03135990 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.